(Press-News.org)
Hepatic cell carcinoma (HCC), the fifth most prevalent malignancy worldwide and the fourth leading cause of cancer-related mortality, poses significant therapeutic challenges. Despite advancements in medical research, late-stage HCC patients have a dismal five-year survival rate of less than 20%. The complexity of liver cancer development involves an intricate interplay of genetic and environmental factors. Among these, mitochondrial alterations and mutations in mitochondrial DNA (mtDNA) are increasingly recognized as critical contributors to cancer pathogenesis. These changes not only impair cellular bioenergetics but also influence tumor suppressors and oncogenic proteins, exacerbating the malignancy. Consequently, targeting mitochondrial dysfunction and mtDNA mutations has emerged as a promising therapeutic strategy.
Mitochondria are pivotal for energy production, metabolism, and cell signaling in eukaryotic cells. They contain their own DNA, mtDNA, which encodes essential proteins for oxidative phosphorylation and ATP synthesis. Human mtDNA is a small, circular, double-stranded genome, approximately 16.6 kbp in size, and is maternally inherited. MtDNA comprises three regions: the coding region, the D-loop region, and the non-coding region. The coding region includes 37 genes crucial for mitochondrial protein translation, while the D-loop region regulates mtDNA replication and transcription.
Mitochondrial dysfunction in HCC involves excessive production of reactive oxygen species (ROS) and defects in mitochondrial enzymes. These dysfunctions can lead to altered cellular metabolism and contribute to the progression of cancer. Additionally, changes in microRNA levels have been linked to mtDNA dysfunction and ROS generation, further complicating the cellular environment.
Recent research has focused on various pharmacological approaches to target mitochondrial dysfunction in cancer. One approach involves targeting the electron transport chain (ETC), responsible for ATP production in mitochondria. Inhibiting transcription of proteins involved in mitochondrial biogenesis pathways is another strategy. These therapeutic interventions aim to restore normal mitochondrial function and prevent cancer progression.
One promising area of research is the role of adenosine monophosphate-activated protein kinase (AMPK) in regulating mitochondrial function. AMPK-dependent inhibition of proteins such as NFκB, p38, and ERK1/2 has shown potential in reducing cancer cell proliferation. For instance, the antiplatelet drug cilostazol inhibits hepatic cancer cell proliferation via AMPK and AKT/ERK signaling pathways. Similarly, the anesthetic propofol has been found to inhibit HepG2 cell proliferation by activating AMPK signaling.
Understanding the role of mtDNA in cancer pathogenesis is crucial for developing targeted therapies. mtDNA mutations have been identified as triggering factors in tumor formation, indicating a direct causal relationship. Targeting mtDNA offers a novel approach in cancer therapy, providing insights into cellular responses to mtDNA damage, predicting treatment efficacy, and assessing potential drug resistance.
Recent advancements in mtDNA-targeted therapies have shown promise, with several therapeutic candidates undergoing clinical trials for various cancers. However, there is a notable lack of clinical studies specifically assessing the efficacy of mitochondrial-targeted therapies in HCC. Future research should focus on the activation or inactivation of AMPK in a context-dependent manner to develop innovative treatment regimens for mitigating cancer development.
Despite the complexities of mitochondrial dysfunction and the multifaceted nature of its mechanisms, further exploration into plant-derived anticancer agents and other natural products could yield valuable therapeutic options. This review aims to provide insights that may inform future research and facilitate the development of novel medications and methods targeting mtDNA.
Mitochondrial DNA targeted therapy represents a promising frontier in the treatment of hepatic cell carcinoma. By understanding the intricate role of mtDNA in cancer progression and leveraging this knowledge to develop targeted therapies, we can pave the way for more effective and personalized treatment options for HCC patients. Continued research and clinical trials are essential to fully realize the potential of mtDNA-targeted therapies and improve outcomes for those battling this challenging disease.
Full text
https://www.xiahepublishing.com/1555-3884/GE-2023-00134
The study was recently published in the Gene Expression.
Gene Expression (GE) is an open-access journal. It was launched in 1991 by Chicago Medical School Press, and transferred to Cognizant Communication Corporation in 1994. From August 2022, GE is published by Xia & He Publishing Inc.
GE publishes peer-reviewed and high-quality original articles, reviews, editorials, commentaries, and opinions on its primary research topics including cell biology, molecular biology, genes, and genetics, especially on the cellular and molecular mechanisms of human diseases.
GE has been indexed in Medline (1991-2021), Scopus, Biological Abstracts, Biosis Previews, ProQuest, etc.
Follow us on X: @xiahepublishing
Follow us on LinkedIn: Xia & He Publishing Inc.
END
About The Study: By assigning lower atherosclerotic cardiovascular disease risk predictions, application of the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million U.S. adults.
Corresponding Author: To contact the corresponding author, Arjun K. Manrai, Ph.D., email Arjun_Manrai@hms.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.12537)
Editor’s ...
Losing someone close, like a family member, can make you age faster, says a new study from Columbia University Mailman School of Public Health and the Butler Columbia Aging Center. The study found that people who lost a parent, partner, sibling, or child, showed signs of older biological age compared to those who hadn’t experienced such losses. The research was published in JAMA Network Open.
Biological aging is the gradual decline in how well your cells, tissues, and organs function, leading to a higher risk of chronic diseases. Scientists measure this type of aging using DNA markers known as epigenetic clocks.
“Few studies ...
About The Study: The findings of this study suggest that infants born to mothers with obesity are at increased risk of sudden unexpected infant death (SUID), with a dose-dependent association between increasing maternal body mass index and SUID risk. Maternal obesity should be added to the list of known risk factors for SUID. With maternal obesity rates increasing, research should identify potential causal mechanisms for this association.
Corresponding Author: To contact the corresponding author, Darren Tanner, Ph.D., email darren.tanner@microsoft.com.
To access the ...
About The Study: Fecal microbiota transplantation (FMT) was safe but did not offer clinically meaningful improvements. Further studies—for example, through modified FMT approaches or bowel cleansing—are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in Parkinson disease.
Corresponding Author: To contact the corresponding author, Filip Scheperjans, M.D., Ph.D., email filip.scheperjans@hus.fi.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaneurol.2024.2305)
Editor’s ...
About The Article: The studies highlighted in this special issue of JAMA Network Open demonstrate important scientific progress in the complex integration of social determinants of health and health disparities with biological pathways and health outcomes to improve understanding of the mechanisms underlying health disparities among various underserved populations. Continued progress remains important in integrating different disciplines to transform the field of health disparities research.
Corresponding Author: To contact the corresponding author, Arielle S. Gillman, Ph.D., M.P.H., email arielle.gillman@nih.gov.
To ...
Researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, have developed a model that rapidly converts stem cells to brain cells with protein structures characteristic of Parkinson’s disease (PD), enabling the study of the condition’s unique and highly variable disease pathology in a petri dish. The study details how the model can one day be used to develop personalized diagnostic and treatment methods for Parkinson’s disease. Results are published in Neuron.
“We sought to assess how quickly we could ...
A recently unveiled cardiovascular disease risk calculator that measures a patient’s risk for heart attack and stroke is better calibrated and more precise than its previous version, but if current treatment guidelines for cholesterol and blood pressure therapy remain unchanged, the new calculator may have unintended consequences, according to research from Harvard Medical School.
The analysis, published July 29 in JAMA, estimates that the new risk calculator would render nearly 16 million people newly ineligible under current treatment thresholds that guide clinical decisions about who should get cholesterol ...
Previous research has found that over 80 percent of people with opioid use disorder (OUD) do not receive evidence-based lifesaving medications. While access to these medications is better in New York City than elsewhere in the United States, numerous structural and social barriers impede access to treatment, and more than 100,000 people in the U.S. continue to die from drug overdoses each year.
To help close this alarming treatment gap, researchers at NYU Grossman School of Medicine partnered with the New York ...
Researchers at UC San Francisco have found a link between following a diet that is rich in vitamins and minerals, especially one without much added sugar, and having a younger biological age at the cellular level.
They looked at how three different measures of healthy eating affected an “epigenetic clock” – a biochemical test that can approximate both health and lifespan – and found that the better people ate, the younger their cells looked. Even when people ate healthy diets, ...
A team of biologists from the University of Delhi and Zoological Survey of India, Harvard University, and the University of Minnesota has discovered a unique breeding behavior in a species of frog endemic to the Andaman Islands of India. In a new study published in the Harvard Museum of Comparative Zoology’s journal Breviora, scientists describe a combination of traits that makes reproduction in this frog unique.
The Andamanese Charles Darwin’s frog, Minervarya charlesdarwini, belongs to the family Dicroglossidae, a large radiation of Asian frogs that comprises over ...
